Aberrant cytokeratin expression as a possible prognostic predictor in poorly differentiated colorectal carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 12, 2013, Pages 1815-1822

  Yamagishi, Hidetsugu ^a   Imai, Yasuo ^a   Okamura, Takuya ^a   Fukuda, Kazunori ^a   Ono, Yuko ^a   Ban, Shinichi ^b   Inoue, Tohru ^c   Ueda, Yoshihiko ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b Saiseikai Kawaguchi General Hospital   (Japan)

^c TOKYO KOSEI NENKIN HOSPITAL   (Japan)

Author keywords

Colorectal carcinoma; Cytokeratin 20; Cytokeratin 7; Mismatch repair; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKERATIN 20; CYTOKERATIN 7; PROTEIN MLH1; PROTEIN MSH2;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; COLORECTAL CARCINOMA; FAMILY HISTORY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNET RING CARCINOMA; UNDIFFERENTIATED CARCINOMA;

COLORECTAL CARCINOMA; CYTOKERATIN 20; CYTOKERATIN 7; MISMATCH REPAIR; PROGNOSIS;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SIGNET RING CELL; COLORECTAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KERATIN-20; KERATIN-7; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84897587046     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12319     Document Type: Article

References (33)

1. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31: 11-24.
2. Moll R, Zimbelmann R, Goldschmidt MD etal. The human gene encoding cytokeratin 20 and its expression during fetal development and in gastrointestinal carcinomas. Differentiation 1993; 53: 75-93.
3. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer 2004; 100: 1776-1785.
4. Moll R, Löwe A, Laufer J, Franke WW. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am. J. Pathol. 1992; 140: 427-447.
5. Loy TS, Calaluce RD. Utility of cytokeratin immunostaining in separating pulmonary adenocarcinomas from colonic adenocarcinomas. Am. J. Clin. Pathol. 1994; 102: 764-767.
6. Wauters CC, Smedts F, Gerrits LG, Bosman FT, Ramaekers FC. Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum. Pathol. 1995; 26: 852-855.
7. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod. Pathol. 2000; 13: 962-972.
8. Miettinen M. Keratin 20: immunohistochemical marker for gastrointestinal, urothelial, and Merkel cell carcinomas. Mod. Pathol. 1995; 8: 384-388.
9. Park SY, Kim HS, Hong EK, Kim WH. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum. Pathol. 2002; 33: 1078-1085.
10. O'Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Rates of colon and rectal cancers are increasing in young adults. Am. Surg. 2003; 69: 866-872.
11. Fairley TL, Cardinez CJ, Martin J etal. Colorectal cancer in U.S. adults younger than 50 years of age, 1998-2001. Cancer 2006; 107 (Suppl. 5): 1153-1161.
12. Hamilton SR, Bosmann FT, Boffetta P etal. Carcinoma of the colon and rectum. In: Bozman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System, 4th edn. Lyon: IARC Press, 2010; 134-146.
13. American Joint Committee on Cancer. Colon and Rectum Cancer Staging, 7th edn. 2009. Cited 18 Oct 2012. Available from URL: http://www.cancerstaging.org/staging/index.html
14. Goldstein NS, Long A, Kuan SF, Hart J. Colon signet ring cell adenocarcinoma: immunohistochemical characterization and comparison with gastric and typical colon adenocarcinomas. Appl. Immunohistochem. Mol. Morphol. 2000; 8: 183-188.
15. Harbaum L, Pollheimer MJ, Kornprat P etal. Keratin 20-a diagnostic and prognostic marker in colorectal cancer? Histol. Histopathol. 2012; 27: 347-356.
16. Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J. Clin. Pathol. 2007; 60: 1112-1116.
17. Marcus VA, Madlensky L, Gryfe R etal. Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors. Am. J. Surg. Pathol. 1999; 23: 1248-1255.
18. Kende AI, Carr NJ, Sobin LH. Expression of cytokeratins 7 and 20 in carcinomas of the gastrointestinal tract. Histopathology 2003; 42: 137-140.
19. Vang R, Gown AM, Barry TS etal. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am. J. Surg. Pathol. 2006; 30: 1130-1139.
20. Bayrak R, Yenidünya S, Haltas H. Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas. Pathol. Res. Pract. 2011; 207: 156-160.
21. Lugli A, Tzankov A, Zlobec I, Terracciano LM. Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status. Mod. Pathol. 2008; 21: 1403-1412.
22. Umar A, Boland CR, Terdiman JP etal. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl. Cancer Inst. 2004; 96: 261-268.
23. McGregor DK, Wu TT, Rashid A, Luthra R, Hamilton SR. Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability. Am. J. Surg. Pathol. 2004; 28: 712-718.
24. Min YS, Yi EH, Lee JK etal. CK20 expression enhances the invasiveness of tamoxifen-resistant MCF-7 cells. Anticancer Res. 2012; 32: 1221-1228.
25. Imai Y, Yamagishi H, Fukuda K, Ono Y, Inoue T, Ueda Y. Differential mucin phenotypes and their significance in a variation of colorectal carcinoma. World J. Gastroenterol. 2013; 19: 3957-3968.
26. Mallo GV, Rechreche H, Frigerio JM etal. Molecular cloning, sequencing and expression of the mRNA encoding human Cdx1 and Cdx2 homeobox. Down-regulation of Cdx1 and Cdx2 mRNA expression during colorectal carcinogenesis. Int. J. Cancer 1997; 74: 35-44.
27. Soubeyran P, André F, Lissitzky JC etal. Cdx1 promotes differentiation in a rat intestinal epithelial cell line. Gastroenterology 1999; 117: 1326-1338.
28. Pilozzi E, Onelli MR, Ziparo V, Mercantini P, Ruco L. CDX1 expression is reduced in colorectal carcinoma and is associated with promoter hypermethylation. J. Pathol. 2004; 204: 289-295.
29. Suh ER, Ha CS, Rankin EB, Toyota M, Traber PG. DNA methylation down-regulates CDX1 gene expression in colorectal cancer cell lines. J. Biol. Chem. 2002; 277: 35795-35800.
30. Wong NA, Britton MP, Choi GS etal. Loss of CDX1 expression in colorectal carcinoma: promoter methylation, mutation, and loss of heterozygosity analyses of 37 cell lines. Proc. Natl. Acad. Sci. U.S.A. 2004; 101: 574-579.
31. Chan CW, Wong NA, Liu Y etal. Gastrointestinal differentiation marker Cytokeratin 20 is regulated by homeobox gene CDX1. Proc. Natl. Acad. Sci. U.S.A. 2009; 106: 1936-1941.
32. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 1999; 96: 8681-8686.
33. Weisenberger DJ, Siegmund KD, Campan M etal. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 2006; 38: 787-793.